Insider Selling: Maze Therapeutics (NASDAQ:MAZE) CMO Sells $425,476.76 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 16,141 shares of the company’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $26.36, for a total transaction of $425,476.76. Following the completion of the transaction, the chief marketing officer owned 16,141 shares of the company’s stock, valued at $425,476.76. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Harold Bernstein also recently made the following trade(s):

• On Thursday, August 13th, Harold Bernstein sold 16,142 shares of Maze Therapeutics stock. The shares were sold at an average price of $27.61, for a total value of $445,680.62.
• On Wednesday, July 1st, Harold Bernstein sold 14,609 shares of Maze Therapeutics stock. The stock was sold at an average price of $29.90, for a total transaction of $436,809.10.

Maze Therapeutics Stock Down 3.2%

Shares of MAZE stock traded down $0.85 during trading hours on Thursday, hitting $25.87. 477,427 shares of the company were exchanged, compared to its average volume of 639,798. The stock has a market capitalization of $1.44 billion, a price-to-earnings ratio of -10.27 and a beta of 2.17. The business’s 50-day simple moving average is $28.76 and its two-hundred day simple moving average is $31.34. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. Maze Therapeutics, Inc. has a one year low of $14.16 and a one year high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.76). Sell-side analysts predict that Maze Therapeutics, Inc. will post -2.72 EPS for the current fiscal year.

Institutional Trading of Maze Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of MAZE. Frazier Life Sciences Management L.P. lifted its holdings in shares of Maze Therapeutics by 10.2% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock worth $150,182,000 after acquiring an additional 465,641 shares during the period. TRV GP IV LLC acquired a new stake in shares of Maze Therapeutics in the second quarter valued at approximately $133,502,907. ARCH Venture Management LLC acquired a new position in Maze Therapeutics during the 2nd quarter valued at about $122,983,582. BlackRock Inc. bought a new stake in Maze Therapeutics in the second quarter valued at about $104,525,000. Finally, Jupiter Topco LLC bought a new position in shares of Maze Therapeutics during the second quarter worth $101,764,000.

Analysts Set New Price Targets

Several research analysts have recently issued reports on MAZE shares. BTIG Research reissued a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a research note on Wednesday, August 12th. TD Cowen raised shares of Maze Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Finally, Wall Street Zen downgraded shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Three research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $66.00.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.